KALIVIR is a biopharmaceutical company founded in 2019 dedicated to developing systemically deliverable oncolytic virus immunotherapies. We design a new class of oncolytic virus immunotherapies that combine the natural ability of viruses to kill cancers cell with novel mechanisms to stimulate anti-tumor immunity, modify tumor environment and maximize targeted killing across all tumor types. Our mission is to ensure every cancer cell in patients can be killed with our viruses, and ultimately cure cancer in all cancer patients.